Amtagvi trial results announced by Iovance Biotherapeutics on October 23, 2026, showed a 62.5% objective response rate when the cell therapy was combined with Merck’s Keytruda in advanced melanoma. The Phase 2 findings support the ongoing Phase 3 TILVANCE-301 study, which compares the combination with Keytruda alone in previously untreated patients.
Key Takeaways
- The combination produced a 62.5% objective response rate and a 29.2% complete response rate.
- Median follow-up reached 50.9 months, while median progression-free survival was 19.8 months.
- The ongoing Phase 3 comparison will assess the combination against Keytruda alone.
Table of Contents
- Amtagvi trial findings support further combination testing
- Phase 3 targets an earlier treatment setting
- Existing approval covers previously treated patients
- Conclusion
Amtagvi trial findings support further combination testing
Iovance reported tumor responses with Amtagvi, also known as lifileucel, combined with Keytruda in its Phase 2 melanoma study. Objective response includes both partial and complete responses; the complete response rate represents patients whose detectable cancer disappeared under the study’s assessment criteria.
The follow-up period provides a longer observation window, but it should not be confused with the duration of every patient’s response. Likewise, progression-free survival measures time without disease progression or death, rather than demonstrating an overall survival benefit.
| Item | Details |
|---|---|
| Objective response rate | 62.5% |
| Complete response rate | 29.2% |
| Disease control rate | 83.3% |
| Median progression-free survival | 19.8 months |
| Median follow-up | 50.9 months |
Phase 3 targets an earlier treatment setting
TILVANCE-301 is testing whether adding Amtagvi to Keytruda improves outcomes compared with Keytruda alone in untreated melanoma patients. The Phase 2 response figures do not by themselves establish superiority over Keytruda; that question requires the comparative trial.
For Iovance, the commercial significance is the possibility of extending Amtagvi into an earlier treatment setting. That remains a development objective, not an approved expansion of its use.
Existing approval covers previously treated patients
The FDA’s February 2024 accelerated approval of Amtagvi covered adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody and, when BRAF V600 mutation-positive, a BRAF inhibitor with or without a MEK inhibitor. That authorization is distinct from the untreated-patient combination being evaluated in TILVANCE-301.
Amtagvi is made from a patient’s own tumor-derived T cells, which are collected, manufactured and returned by infusion. The FDA’s approval announcement also identifies serious risks, including severe infections, prolonged severe low blood counts and potentially fatal treatment-related complications, reflected in a boxed warning.
Conclusion
The next confirmed development step is the ongoing TILVANCE-301 comparison. Its findings will be important in determining whether the Phase 2 response results translate into an advantage over Keytruda alone in untreated melanoma.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
